 |
|
Breast cancer
While no clinical study on the anti-tumour effect of Avemar was conducted for breast cancer, there was an open quality-of-life study performed at the Uiversity of Szeged's Clinic of Surgery by Prof. Ádám Balogh, M.D. 55 individuals were enrolled in the study, with a mean age of 55.4 years and an average follow-up period of 32.2 months. The study was based on an EORTC QLQ-C 30 questionnaire. The patient's clinical stage was not a criterion for inclusion, UICC stages I-IV being represented in an almost even distribution. Less than half of patients received simultaneous chemotherapy and/ or radiotherapy.
The patients showed significant improvement in
- Physical function (p<0.05),
- Emotional functions (p<0.001),
- Global state of health (p<0.01), while the following parameters were considerably reduced:
- Global state of health (p<0.01), while the following parameters were considerably reduced:
- fatigue (p<0.01),
- nausea and vomiting (p<0.01),
- insomnia (p<0.01)
- constipation(p?0.01).
Other parameters not indicated in EORTC-QLQ C30 questionnaire were:
- hair loss (p<0.001),
- antiemetic consumption (p<0.001),
- use of tranquillizers (p<0.05).
The indicated effects manifested themselves within 3 months of beginning treatment and were maintained during the whole observation period.
|
 |
|
 |
